Incidence and clinical significance of false-negative sextant prostate biopsies

Journal of Urology

Volumn 159, Issue 4, 1998, Pages 1247-1250

  Rabbani, Farhang ^a   Stroumbakis, Nicholas ^a   Kava, Bruce R ^a   Cookson, Michael S ^a   Fair, William R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Biopsy; Needle; Prostate; Prostatic neoplasms; Ultrasonography

Indexed keywords

FLUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BIOPSY TECHNIQUE; CANCER HORMONE THERAPY; CANCER STAGING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; INCIDENCE; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT OUTCOME;

EID: 0031897085     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63574-2     Document Type: Article

References (20)

1. Hodge, K. K., McNeal, J. E., Terris, M. K. and Stamey, T. A.: Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J. Urol., 142: 71, 1989.
2. Garber, S. J., Goldenberg, S. L., Cooperberg, P. L., Wong, A. D., Bilby, J. H. and Mathieson, J. R.: Systematic transrectal ultrasound-guided biopsy of the prostate. Canad. Ass. Rad. J., 45: 387, 1994.
3. Slonim, S. M., Cuttino, J. T., Jr., Johnson, C. J., Yankaskas, B. C., Smith, J. J., III, Silverman, M. L. and Libertino, J. A.: Diagnosis of prostatic carcinoma: value of random transrectal sonographically guided biopsies. AJR, 161: 1003, 1993.
4. Rifkin, M. D., Alexander, A. A., Pisarchick, J. and Matteucci, T.: Palpable masses in the prostate: superior accuracy of US-guided biopsy compared with accuracy of digitally guided biopsy. Radiology, 179: 41, 1991.
5. Roehrborn, C. G., Pickens, G. J. and Sanders, J. S.: Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels. Urology, 47: 347, 1996.
6. Ellis, W. J. and Brawer, M. K.: Repeat prostate needle biopsy: who needs it? J. Urol., 153: 1496, 1995.
7. Keetch, D. W., Catalona, W. J. and Smith, D. S.: Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J. Urol., 151: 1571, 1994.
8. Fleshner, N. E. and Fair, W. R.: Indications for transition zone biopsy in the detection of prostatic carcinoma. J. Urol., 157: 556, 1997.
9. Stamey, T. A., Freiha, F. S., McNeal, J. E., Redwine, E. A., Whittemore, A. S. and Schmid, H. P.: Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer, 71: 933, 1993.
10. Terris, M. K., McNeal, J. E. and Stamey, T. A.: Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J. Urol., 148: 829, 1992.
11. Stricker, H. J., Ruddock, L. J., Wan, J. and Belville, W. D.: Detection of non-palpable prostate cancer. A mathematical and laboratory model. Brit. J. Urol., 71: 43, 1993.
12. Kava, B. R., Stroumbakis, N., Dalbagni, G., Cookson, M., Sogani, P. C., Russo, P., Herr, H., Sheinfeld, J., Reuter, V., Rosai, J., Begg, C. and Fair, W. R.: Prospective randomized clinical trial comparing primary therapy with Zoladex + flutamide and radical prostatectomy versus radical prostatectomy alone in patients with clinically localized prostate cancer. J. Urol., part 2, 157: 253, abstract 990, 1997.
13. Stroumbakis, N., Cookson, M. S., Reuter, V. E. and Fair, W. R.: Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology, suppl., 49: 113, 1997.
14. Andros, E. A., Danesghari, F. and Crawford, E. D.: Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate. Clin. Invest. Med., 16: 510, 1993.
15. Cooner, W. H.: Prostate-specific antigen, digital rectal examination, and transrectal ultrasonic examination of the prostate in prostate cancer detection. Monogr. Urol., 12: 3, 1991.
16. Uzzo, R. G., Wei, J. T., Waldbaum, R. S., Perlmutter, A. P., Bryne, J. C. and Vaughn, E. D., Jr.: The influence of prostate size on cancer detection. Urology, 46: 831, 1995.
17. Stamey, T. A.: Making the most out of six systematic sextant biopsies. Urology, 45: 2, 1995.
18. Eskew, L. A., Bare, R. L. and McCullough, D. L.: Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J. Urol., 157: 199, 1997.
19. Cookson, M. S., Sogani, P. C., Russo, P., Sheinfeld, J., Herr, H., Dalbagni, G., Reuter, V. E., Begg, C. B. and Fair, W. R.: Pathological staging and biochemical recurrence after neoadjuvant deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. Brit. J. Urol., 79: 432, 1997.
20. Gleave, M. E., Goldenberg, S. L., Jones, E. C., Bruchovsky, N. and Sullivan, L. D.: Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J. Urol., 155: 213, 1996.